6.6.7. metastasis-directed therapy m1-patients. patients relapsing local treatment, metastases-targeting therapy proposed, aim delay systemic treatment. retrospective analysis 211 patients treated mdt, milenkovic et al. aimed defining prognostic factors mfs, palliative adt-free (padt) survival cause-specific survival (css). median follow-up 42 months mdt, patients cn1 significantly superior 5-years mfs, padt css compared patients m1 disease (p<0.02). interest, 23% patients free biochemical recurrence five years . two randomised phase ii trials testing metastasis-directed therapy (mdt) using surgery ± sabr vs. surveillance sabr vs. surveillance men oligo-recurrent pca . oligo-recurrence defined < 3 lesions choline-pet/ct conventional imaging mri/ct and/or bone scan . sample size small 62 54 patients, respectively, substantial proportion nodal disease . androgen deprivation therapy-free survival primary endpoint one study longer mdt surveillance . primary endpoint oriole trial progression six months significantly lower sbrt surveillance (19% vs. 61%, p = 0.005) . recently combined results stomp oriole confirmed significant improvement pfs favour mdt (hr: 0.44, p < 0.001) . phase ii trial assessed biochemical response 18f-dcfpyl pet/mri subsequent mdt. overall biochemical response rate, defined ≥ 50% psa decline, 60%, including 22% patients complete biochemical response . currently data suggest improvement os. two comprehensive reviews highlighted mdt (sabr) promising therapeutic approach must still considered investigational results ongoing rct available . thus far, toxicity mdt appears low, also needs confirmed .